CN101052403A - 提高5,5－二苯基巴比妥酸的生物利用度和增强其脑递送的组合物及方法 - Google Patents

提高5,5－二苯基巴比妥酸的生物利用度和增强其脑递送的组合物及方法 Download PDF

Info

Publication number
CN101052403A
CN101052403A CNA2005800340587A CN200580034058A CN101052403A CN 101052403 A CN101052403 A CN 101052403A CN A2005800340587 A CNA2005800340587 A CN A2005800340587A CN 200580034058 A CN200580034058 A CN 200580034058A CN 101052403 A CN101052403 A CN 101052403A
Authority
CN
China
Prior art keywords
acid
dpb
diphenylbarbituric acid
diphenylbarbituric
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800340587A
Other languages
English (en)
Chinese (zh)
Inventor
丹尼拉·古特曼
阿夫拉汉姆·亚科比
丹尼尔·莫罗斯
巴里·莱维特
霍华德·鲁特曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taro Pharmaceutical Industries Ltd
Original Assignee
Taro Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taro Pharmaceutical Industries Ltd filed Critical Taro Pharmaceutical Industries Ltd
Publication of CN101052403A publication Critical patent/CN101052403A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids
    • C07D239/64—Salts of organic bases; Organic double compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CNA2005800340587A 2004-08-10 2005-08-10 提高5,5－二苯基巴比妥酸的生物利用度和增强其脑递送的组合物及方法 Pending CN101052403A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60032704P 2004-08-10 2004-08-10
US60/600,327 2004-08-10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2011103358486A Division CN102512422A (zh) 2004-08-10 2005-08-10 提高5,5-二苯基巴比妥酸的生物利用度和增强其脑递送的组合物及方法

Publications (1)

Publication Number Publication Date
CN101052403A true CN101052403A (zh) 2007-10-10

Family

ID=34942111

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2005800340587A Pending CN101052403A (zh) 2004-08-10 2005-08-10 提高5,5－二苯基巴比妥酸的生物利用度和增强其脑递送的组合物及方法
CN2011103358486A Pending CN102512422A (zh) 2004-08-10 2005-08-10 提高5,5-二苯基巴比妥酸的生物利用度和增强其脑递送的组合物及方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2011103358486A Pending CN102512422A (zh) 2004-08-10 2005-08-10 提高5,5-二苯基巴比妥酸的生物利用度和增强其脑递送的组合物及方法

Country Status (14)

Country Link
EP (2) EP1625848A1 (https=)
JP (2) JP2008509914A (https=)
KR (2) KR20120130256A (https=)
CN (2) CN101052403A (https=)
AT (1) ATE510541T1 (https=)
AU (1) AU2005280419B2 (https=)
BR (1) BRPI0513337A (https=)
CA (1) CA2576832C (https=)
IL (1) IL181247A (https=)
MX (1) MX2007001655A (https=)
NZ (1) NZ553653A (https=)
SG (1) SG163500A1 (https=)
WO (1) WO2006026095A2 (https=)
ZA (1) ZA201106419B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109804249A (zh) * 2017-06-14 2019-05-24 清滔制药株式会社 用于测定人体体液氧化应激的方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7683071B2 (en) 2000-07-26 2010-03-23 Taro Pharmaceuticals Industries Ltd. Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
US6756379B2 (en) 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
WO2004052350A2 (en) 2002-12-11 2004-06-24 Taro Pharmaceutical Industries Limited Method of treating movement disorders using barbituric acid derivatives
EP1625848A1 (en) * 2004-08-10 2006-02-15 Taro Pharmaceuticals North America, Inc. Composition and method for enhanced delivery of 5,5-diphenyl barbituric acid
CN102863579B (zh) * 2012-09-14 2014-02-05 东南大学 一种巴比妥酸螯合树脂及其制备方法和应用
KR102162003B1 (ko) 2014-04-14 2020-10-06 삼성전자주식회사 무선 네트워크 연결 제어 방법 및 장치
GB202100352D0 (en) * 2021-01-12 2021-02-24 Balticgruppen Bio Ab New methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2119701A (en) * 1934-06-29 1938-06-07 Winthrop Chem Co Inc Alkoxyalkyl mercury nitrogen compounds
IL69722A (en) * 1983-09-14 1986-09-30 Taro Pharma Ind Oxopyrimidine derivatives and pharmaceutical compositions containing them
DE4433764A1 (de) * 1994-09-22 1996-03-28 Asta Medica Ag Darreichungsformen enthaltend alpha-Liponsäure, feste Salze von R-Thioctsäure mit verbesserter Freisetzung und Bioverfügbarkeit
US6093820A (en) * 1997-10-02 2000-07-25 Taro Pharmaceutical Industries Ltd. Method and reagents for N-alkylating ureides
WO2002007729A1 (en) * 2000-07-26 2002-01-31 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
US6756379B2 (en) * 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
EP1485101A4 (en) * 2002-01-30 2006-04-12 Taro Pharma Ind NON-SURFACTANT BARBITIC ACID DERIVATIVES
WO2004052350A2 (en) * 2002-12-11 2004-06-24 Taro Pharmaceutical Industries Limited Method of treating movement disorders using barbituric acid derivatives
EP1625848A1 (en) * 2004-08-10 2006-02-15 Taro Pharmaceuticals North America, Inc. Composition and method for enhanced delivery of 5,5-diphenyl barbituric acid

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109804249A (zh) * 2017-06-14 2019-05-24 清滔制药株式会社 用于测定人体体液氧化应激的方法

Also Published As

Publication number Publication date
EP1625848A1 (en) 2006-02-15
IL181247A0 (en) 2007-07-04
EP1781294A2 (en) 2007-05-09
MX2007001655A (es) 2007-04-23
HK1108313A1 (en) 2008-05-02
CA2576832A1 (en) 2006-03-09
EP1781294B1 (en) 2011-05-25
CA2576832C (en) 2013-06-11
ZA201106419B (en) 2012-05-30
BRPI0513337A (pt) 2008-05-06
WO2006026095A2 (en) 2006-03-09
IL181247A (en) 2012-05-31
AU2005280419B2 (en) 2010-09-23
AU2005280419A1 (en) 2006-03-09
SG163500A1 (en) 2010-08-30
KR20120130256A (ko) 2012-11-29
EP1781294A4 (en) 2007-12-26
CN102512422A (zh) 2012-06-27
JP2008509914A (ja) 2008-04-03
KR20070074549A (ko) 2007-07-12
NZ553653A (en) 2010-06-25
ATE510541T1 (de) 2011-06-15
JP2013177442A (ja) 2013-09-09
WO2006026095A3 (en) 2007-02-01

Similar Documents

Publication Publication Date Title
CN1142783C (zh) 用于治疗高危葡萄糖耐量降低的药剂
CN1127340C (zh) 含烟碱复合物的组合物、该组合物的应用及其形成方法
US11273159B2 (en) Pharmaceutical formulations
CN1250371A (zh) 用于控制释放活性物质的药物组合物
US20180256583A1 (en) Treatments for autoimmune disease
CN1809341A (zh) 多层口溶型片剂
US20090124639A1 (en) valacyclovir formulations
CN102341098A (zh) 具有高负荷的加巴喷丁前药的口服剂型
JP2013177442A (ja) ５，５−ジフェニルバルビツル酸の改良されたバイオアベイラビリティ及び高められた脳送達のための組成物及び方法
CN1646143A (zh) β－2肾上腺素受体兴奋剂与氨基糖的结合及其在治疗免疫功能紊乱方面的应用
US8076346B2 (en) Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
CN1323200A (zh) 5ht4激动剂或拮抗剂的新型口服制剂
KR20150139830A (ko) 신경변성 및 기타 질환의 치료를 위한 조성물 및 방법
CN1520285A (zh) 包含西替利嗪和伪麻黄碱的片剂
CN1150194C (zh) 碳环核苷半硫酸盐和它在治疗病毒性感染中的应用
CN1717235A (zh) 使用巴比土酸衍生物治疗运动障碍的方法
CN101065114A (zh) 6－巯基嘌呤的改进制剂
CN1420763A (zh) 每天给药一次环丙沙星的口服给药控释系统
JP2007529545A (ja) ダウン症候群の治療法
CN1286844C (zh) 含有血管紧张素ⅱ受体拮抗剂和b族维生素的药物组合物
CN1291720C (zh) 非镇静性巴比土酸衍生物
HK1110515A (en) Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
WO2022124325A1 (ja) 細胞内ａｔｐ増強剤
US10391178B2 (en) Premix of crystalline raltegravir potassium salt and a process for the preparation thereof
HK1171958A (en) Composition and method for improved bioavailability and enhanced brain delivery of 5, 5-diphenyl barbituric acid

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1110515

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20071010

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1110515

Country of ref document: HK